These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 34830800)

  • 21. Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
    Tamura K
    Jpn J Clin Oncol; 2019 Dec; 49(11):993-998. PubMed ID: 31665472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The emerging CDK4/6 inhibitor for breast cancer treatment.
    Sheikh MS; Satti SA
    Mol Cell Pharmacol; 2021; 13(3):9-12. PubMed ID: 35251463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
    Hecht KA; Selby C
    Ann Pharmacother; 2019 Feb; 53(2):195-203. PubMed ID: 30079740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of ER positive metastatic breast cancer.
    McAndrew NP; Finn RS
    Semin Oncol; 2020 Oct; 47(5):270-277. PubMed ID: 32958261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
    Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
    Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
    Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
    Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
    Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
    J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
    O'Brien NA; McDermott MSJ; Conklin D; Luo T; Ayala R; Salgar S; Chau K; DiTomaso E; Babbar N; Su F; Gaither A; Hurvitz SA; Linnartz R; Rose K; Hirawat S; Slamon DJ
    Breast Cancer Res; 2020 Aug; 22(1):89. PubMed ID: 32795346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review.
    Reinert T; Barrios CH
    Ther Adv Med Oncol; 2017 Nov; 9(11):693-709. PubMed ID: 29344106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Review of Fulvestrant in Breast Cancer.
    Nathan MR; Schmid P
    Oncol Ther; 2017; 5(1):17-29. PubMed ID: 28680952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer.
    Ditsch N; Schmidt M
    Geburtshilfe Frauenheilkd; 2019 Dec; 79(12):1328-1335. PubMed ID: 31875862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
    Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS
    Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future.
    Rozeboom B; Dey N; De P
    Am J Cancer Res; 2019; 9(12):2821-2831. PubMed ID: 31911865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review.
    Nagaraj G; Ma CX
    Adv Ther; 2021 Jan; 38(1):109-136. PubMed ID: 33190190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer.
    Ballinger TJ; Meier JB; Jansen VM
    Front Oncol; 2018; 8():308. PubMed ID: 30148117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant.
    Degenhardt T; Fasching PA; Lüftner D; Müller V; Thomssen C; Schem C; Witzel I; Decker T; Tesch H; Kümmel S; Uleer C; Wuerstlein R; Hoffmann O; Warm M; Marschner N; Schinköthe T; Kates RE; Schumacher J; Otremba B; Zaiss M; Harbeck N; Schmidt M;
    Trials; 2023 May; 24(1):338. PubMed ID: 37198674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding the benefits and challenges of first-line cyclin-dependent kinases 4 and 6 inhibitors in advanced breast cancer among postmenopausal women.
    Azim HA; Dawood S; El-Saghir N; Kassem L; Azim HA
    Breast J; 2020 Apr; 26(4):630-642. PubMed ID: 31709685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives.
    Iorfida M; Mazza M; Munzone E
    Breast Cancer (Dove Med Press); 2020; 12():45-56. PubMed ID: 32256106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.